Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study. - Wikidata - wikimedia - TriplyDB

Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study.

Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study.

http://www.wikidata.org/entity/Q35669559

about

The past and the future of Alzheimer's disease CSF biomarkers-a journey toward validated biochemical tests covering the whole spectrum of molecular events Extracellular Vesicle-Associated Aβ Mediates Trans-Neuronal Bioenergetic and Ca2+-Handling Deficits in Alzheimer's Disease Models.Cerebrospinal Fluid Aβ40 Improves the Interpretation of Aβ42 Concentration for Diagnosing Alzheimer's Disease Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer's disease.Active duty service members who sustain a traumatic brain injury have chronically elevated peripheral concentrations of Aβ40 and lower ratios of Aβ42/40.Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice.Selecting Aβ isoforms for an Alzheimer's disease cerebrospinal fluid biomarker panel.Dynamic Nature of presenilin1/γ-Secretase: Implication for Alzheimer's Disease Pathogenesis.Alzheimer's Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid.Detection of Plasma Biomarkers Using Immunomagnetic Reduction: A Promising Method for the Early Diagnosis of Alzheimer's Disease.Interplay between protein glycosylation pathways in Alzheimer's disease.Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.Cross-seeding between Aβ40 and Aβ42 in Alzheimer's disease.Prostaglandin J2 promotes O-GlcNAcylation raising APP processing by α- and β-secretases: relevance to Alzheimer's disease.Fluid biomarker agreement and interrelation in dementia due to Alzheimer's disease.Performance Evaluation of an Automated ELISA System for Alzheimer's Disease Detection in Clinical Routine.Reproducibility of Alzheimer's Disease Cerebrospinal Fluid-Biomarker Measurements under Clinical Routine Conditions.Neurodegenerative disease biomarkers Aβ1-40, Aβ1-42, tau, and p-tau181 in the vervet monkey cerebrospinal fluid: Relation to normal aging, genetic influences, and cerebral amyloid angiopathy.Impact of cerebrospinal fluid matrix on the detection of Alzheimer's disease with Aβ42 and influence of disease on the total-Aβ42/Aβ40 ratio.Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment.The Past and the Future of Alzheimer's Disease Fluid Biomarkers.Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic.Relevance of Aβ42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLMR Scale.Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer's Disease Diagnosis.

P2860

Q26781635-0D8D8547-65FF-46AF-9819-B62C807792FE Q30830788-AE444B65-9C6F-443E-8838-844A1225FBF3 Q36322982-75299C3A-73A8-418B-A6D7-B1570BFFB278 Q37487835-72301922-5CD7-41A3-B8F7-4448CD6E2570 Q37494841-BD9548E8-4E97-4118-8294-3D26DA629206 Q38825497-15F5BEE2-5FA5-4CF4-9EB3-8119C158C374 Q39098473-AFFAF3A3-E06C-4D45-B8E2-9CECA76C355E Q39195180-C16FE106-8C8E-4B92-B373-93596C909F39 Q39217840-64C37CAD-7A7A-4E28-8570-6A3DBFECA36C Q39451605-C6ABF684-3733-47BF-A58B-B4C2728E83AB Q41723383-1E8E420E-DB39-4D3C-81DB-35F58EF58B3B Q42374123-720AF4CA-FECA-4885-B268-EA60569010BA Q44369500-4FF82D5A-52DB-4017-9DA6-D457D111053A Q47391212-309AA3D2-4BEF-4156-805A-AAE002132EBA Q47573970-AAFB11EC-4CDF-4DF2-817C-97C38061529F Q47976273-84FAD8A1-ADB6-46E5-9EF5-EB136148FB7A Q50034469-1818996B-6E2E-4752-828B-6876841157CF Q50349550-C327EEDF-E1DA-4382-A8F1-C1FF22394E61 Q50711684-4935F9F1-4E76-49E7-BF32-99384CC7F3D0 Q51737722-7B837C25-8A77-4648-A20D-250B96F41382 Q52644601-0743FBFF-AF3F-4D7C-8A94-E8018438D18E Q53430039-28BE9C2E-C511-4C5A-B310-03DA22657E3C Q54960062-AFF5BF46-5AE6-4874-A2C6-45136B1569C5 Q55383590-E30C94F5-F35A-41FD-A4F7-C9339EB1B76D

P2860

Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study.

http://www.wikidata.org/entity/Q35669559

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Cerebrospinal fluid amyloid-β ...... centers: a multicentric study.

@ast

Cerebrospinal fluid amyloid-β ...... centers: a multicentric study.

@en

type

label

Cerebrospinal fluid amyloid-β ...... centers: a multicentric study.

@ast

Cerebrospinal fluid amyloid-β ...... centers: a multicentric study.

@en

prefLabel

Cerebrospinal fluid amyloid-β ...... centers: a multicentric study.

@ast

Cerebrospinal fluid amyloid-β ...... centers: a multicentric study.

@en

P1433

Q35669559-47C7B29E-4A48-4875-AA0F-2FCC3233E9F1

P1476

Q35669559-E64EC30F-2D53-4271-9336-DDEA5AB8849F

P2093

Q35669559-24433EF6-F3E8-4F19-AEBF-F6690EC913C5

Q35669559-474D4214-3219-4D8F-8821-B426416C132B

Q35669559-4A8F44BA-593A-4FB1-B1AC-47878F70071D

Q35669559-4FEF48BE-1292-4B46-8D4E-64604601D134

Q35669559-57C3A1DB-B9EA-4E4F-B679-02C666EBBFF6

Q35669559-830BBB02-736A-425E-97C8-4EA4BC6ABCB3

Q35669559-8EF8D02F-3AE4-4195-B32E-2CD006C921C1

Q35669559-C587EE02-62A2-4642-88D7-CBC254DF63A3

Q35669559-F503B9F7-67CB-45F4-A237-B23FC5770935

P2860

Q35669559-09EE0375-74EE-438D-BDE5-A6649780579D

Q35669559-0C661480-42E8-4FE8-8EBD-DAF5A02537A9

Q35669559-0ED96F95-BC93-44AF-AFB1-223DB04E7182

Q35669559-100EDC1B-3978-4D6D-BC78-CB1E9EB88480

Q35669559-11D45A0D-D2B4-4D61-8CAF-429259E47BA0

Q35669559-1FAB9381-2BD8-47E4-A310-BC67833618C4

Q35669559-29A510B1-EEBB-42EE-93E8-C7B3EFA17A6B

Q35669559-350C4BC8-D142-4B1D-BB7B-56B8D4C94376

Q35669559-3B0FBF23-A220-4FD2-AECC-05E5D1DF4410

Q35669559-42758805-5165-4336-8DD1-EC4D981E690F

P2888

Q35669559-124D6FCA-D016-4AE5-AAD0-123260C423DE

P304

Q35669559-7C940FAE-1E1A-4099-8637-64C3A800E0AC

P31

Q35669559-E40475D5-F17D-43F4-9124-F1269396B6A6

P356

Q35669559-417EB81B-3967-4D15-976F-D69E6E9E6A08

P407

Q35669559-10718EF0-2695-41FC-B3B2-A7330E096BF3

P433

Q35669559-EDCCB362-00A8-4176-8012-A0E1773560D5

P478

Q35669559-9AA3F70B-69BB-4701-AD69-AEC4A1702206

P50

Q35669559-3A28D126-E0C3-4A03-9B73-70255EF54E0C

Q35669559-62B241A0-5052-4AA9-9696-C09263F1CB50

Q35669559-8AE03229-03BB-46E4-8746-6234CD5C3620

Q35669559-8FFBA5D6-2C3E-44E4-8141-54EE92CA3753

Q35669559-EAD37495-C39A-4FB7-B5D0-EDDD09BE5DA3

Q35669559-F11C5EF8-2D85-4734-8C56-5C79871CB875

P577

Q35669559-1CD7D15B-73FA-4953-BBAD-B117CC5E35B0

P5875

Q35669559-3C54F653-775A-47F5-AE60-380545E8B4BC

P6179

Q35669559-B114C18D-9A78-43D3-B35C-0D1787929FC4

P698

Q35669559-715D984F-97BC-4124-97E6-8AFAB8371A1A

P921

Q35669559-E7DD1EAC-487F-447A-B9CC-F660E0A6FC6A

P932

Q35669559-56974B81-06D7-4C4F-A02B-E1026D027569

P356

S13195-015-0114-5

P1433

Alzheimers Research & Therapy

P1476

Cerebrospinal fluid amyloid-β ...... centers: a multicentric study.

@en

P2093

Claire Paquet

http://www.w3.org/2001/XMLSchema#string

Jacques Hugon

http://www.w3.org/2001/XMLSchema#string

Jacques Touchon

http://www.w3.org/2001/XMLSchema#string

Jean-Louis Laplanche

http://www.w3.org/2001/XMLSchema#string

Ksenia V Kastanenka

http://www.w3.org/2001/XMLSchema#string

Olivier Vercruysse

http://www.w3.org/2001/XMLSchema#string

Stéphanie Bombois

http://www.w3.org/2001/XMLSchema#string

Susanna Schraen

http://www.w3.org/2001/XMLSchema#string

Sylvain Lehmann

http://www.w3.org/2001/XMLSchema#string

P2860

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond

Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective

Clinical and biomarker changes in dominantly inherited Alzheimer's disease.

Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010.

A diagnostic scale for Alzheimer's disease based on cerebrospinal fluid biomarker profiles.

Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers.

Fluid biomarkers in Alzheimer's disease - current concepts

CSF biomarker variability in the Alzheimer's Association quality control program.

The global prevalence of dementia: a systematic review and metaanalysis.

P2888

s13195-015-0114-5

P304

30

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13195-015-0114-5

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Florence Pasquier

Julien Dumurgier

Bernard Sablonniere

P577

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

276880434

http://www.w3.org/2001/XMLSchema#string

P6179

1040421883

http://www.w3.org/2001/XMLSchema#string

P698

26034513

http://www.w3.org/2001/XMLSchema#string

P921

cerebrospinal fluid

P932

4450486

http://www.w3.org/2001/XMLSchema#string